You\u27ve got to breathe, you know  - asthma patients and carers\u27 perceptions around purchase and use of asthma preventer medicines by Davis, Sharon et al.
University of Wollongong 
Research Online 
Faculty of Science, Medicine and Health - 
Papers: Part B Faculty of Science, Medicine and Health 
1-1-2019 
"You've got to breathe, you know" - asthma patients and carers' perceptions 
around purchase and use of asthma preventer medicines 
Sharon Davis 
University of Sydney 
Jacqueline Tudball 
University of Sydney 
Anthony Flynn 
Asthma Australia Ltd 
Kirsty Lembke 
NPS MedicineWise 
Nicholas Arnold Zwar 
University of Wollongong, nzwar@uow.edu.au 
See next page for additional authors 
Follow this and additional works at: https://ro.uow.edu.au/smhpapers1 
Publication Details Citation 
Davis, S., Tudball, J., Flynn, A., Lembke, K., Zwar, N. A., & Reddel, H. K. (2019). "You've got to breathe, you 
know" - asthma patients and carers' perceptions around purchase and use of asthma preventer 
medicines. Faculty of Science, Medicine and Health - Papers: Part B. Retrieved from 
https://ro.uow.edu.au/smhpapers1/593 
Research Online is the open access institutional repository for the University of Wollongong. For further information 
contact the UOW Library: research-pubs@uow.edu.au 
"You've got to breathe, you know" - asthma patients and carers' perceptions 
around purchase and use of asthma preventer medicines 
Abstract 
Objective: To explore influences on patients' purchase and use of asthma preventer medicines and the 
perceived acceptability of financial incentives via reduced patient co-payments. 
Methods: Semi-structured telephone or face-to-face interviews were conducted with adults and carers of 
children with asthma. Interviews were recorded, transcribed verbatim and coded. Data were analysed 
using thematic analysis via grounded theory. 
Results: Twenty-four adults and 20 carers for children aged 3-17 years with asthma were interviewed. For 
medicines choice, most participants did not consider themselves the primary decision-maker; cost of 
medicines was an issue for some, but effectiveness was described as more important. For adherence, 
cost, side-effects, perceived benefit and patient behaviours were important. 
Conclusions: Patient barriers to adherence with asthma preventer medicines including cost are ongoing. 
Healthcare professionals need to encourage empathic discussion with patients about cost issues. 
Implications for public health: Asthma patients and carers could benefit from greater involvement and 
respect within shared decision-making. Healthcare professionals should be aware that cost may be a 
barrier for patient adherence, and provided with information about the relative costs of guideline-
recommended asthma medicines. Patients and healthcare professionals need education around the 
efficacy of ICS-alone treatment and the rationale behind co-payments, for initiatives around quality use of 
medicines to succeed. 
Publication Details 
Davis, S. R., Tudball, J., Flynn, A., Lembke, K., Zwar, N. & Reddel, H. (2019). “You’ve got to breathe, you 
know” – asthma patients and carers’ perceptions around purchase and use of asthma preventer 
medicines. Australian and New Zealand Journal of Public Health, 43 (3), 207-213. 
Authors 
Sharon Davis, Jacqueline Tudball, Anthony Flynn, Kirsty Lembke, Nicholas Arnold Zwar, and Helen K. 
Reddel 
This journal article is available at Research Online: https://ro.uow.edu.au/smhpapers1/593 
2019 vol. 43 no. 3 Australian and New Zealand Journal of Public Health 207
© 2019 The Authors
Asthma is a chronic condition affecting 11% of Australian adults and children.1 In addition to day-
to-day symptoms, asthma carries the risk 
of serious flare-ups (also called attacks or 
exacerbations) that may be life-threatening. 
Guidelines therefore recommend that most 
patients with asthma should be prescribed 
regular inhaled corticosteroids (ICS), as well 
as a reliever medicine for as-needed use.2,3 
Australian guidelines3 endorse a stepped 
approach to treatment, including regular 
‘preventer’ treatment with low-dose ICS-alone 
for most adult patients and low-dose ICS or 
leukotriene receptor antagonist (LTRA) for 
children. However, in Australia, most patients 
are prescribed a combination of ICS/long-
acting beta 2-agonist (LABA) rather than 
ICS-alone. Of all the individuals who had any 
ICS dispensed in 2013, 81.4% were dispensed 
ICS/LABA.4
Despite higher adherence to ICS being 
associated with lower asthma mortality, fewer 
emergency department visits and hospital 
admissions,5,6 poor adherence is extremely 
common and is associated with greater risk of 
severe exacerbations.7 Analysis of Australian 
dispensing records has shown that among 
people aged ≥65 years who received any ICS-
containing medicine in 2013 only 30% could 
have used it regularly (≥7 prescriptions filled 
annually).4 Rates were even lower for people 
aged 35-64 (15.8%) and 15-34 years (7.3%). A 
nationally-representative self-report survey 
of adults with asthma also confirmed poor 
adherence to asthma medicines.8
Multiple factors are acknowledged to affect 
medicine adherence in asthma, including 
perceived necessity of medicines, ease of 
use, concerns about and experience of side 
effects, forgetting and busy lifestyles.9,10 
Out-of-pocket costs for patients are also 
known to affect medicine adherence and 
management decisions in asthma,11,12 even 
after adjustment for socioeconomic status.13 
In Australia, all ICS-containing asthma 
medicines are subsidised through the 
Pharmaceutical Benefits Scheme (PBS), with 
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Abstract
Objective: To explore influences on patients’ purchase and use of asthma preventer medicines 
and the perceived acceptability of financial incentives via reduced patient co-payments.
Methods: Semi-structured telephone or face-to-face interviews were conducted with adults 
and carers of children with asthma. Interviews were recorded, transcribed verbatim and coded. 
Data were analysed using thematic analysis via grounded theory.
Results: Twenty-four adults and 20 carers for children aged 3-17 years with asthma were 
interviewed. For medicines choice, most participants did not consider themselves the primary 
decision-maker; cost of medicines was an issue for some, but effectiveness was described as 
more important. For adherence, cost, side-effects, perceived benefit and patient behaviours 
were important. 
Conclusions: Patient barriers to adherence with asthma preventer medicines including cost are 
ongoing. Healthcare professionals need to encourage empathic discussion with patients about 
cost issues. 
Implications for public health: Asthma patients and carers could benefit from greater 
involvement and respect within shared decision-making. Healthcare professionals should be 
aware that cost may be a barrier for patient adherence, and provided with information about 
the relative costs of guideline-recommended asthma medicines. Patients and healthcare 
professionals need education around the efficacy of ICS-alone treatment and the rationale 
behind co-payments, for initiatives around quality use of medicines to succeed. 
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the current maximum patient co-payment 
per dispensed prescription being $40.30 for 
eneral beneficiaries and $6.50 for concession 
card holders (see Box 1). The monthly out-
of-pocket cost for ICS-alone can be as little 
as 15% of that of ICS/LABA preventers14 but 
recent qualitative research suggests that 
Australian GPs are not aware of the cost of 
different treatment options and few discuss 
cost of medicines with their patients.15  
Little is known about the patient’s 
perspective on asthma preventer choices 
and on the effect of cost on medicine choice 
or adherence. This study aimed, through 
qualitative interviews with adults with asthma 
and carers of children with asthma, to explore 
factors that influence patients’ choice and use 
of preventer medicines. In addition, the study 
explored the feasibility and acceptability to 
patients of financial incentives to encourage 
use of low-dose ICS-alone rather than ICS/




Semi-structured telephone or face-to-face 
interviews were conducted with a purposive 
sample of adults with asthma and carers 
of children with asthma. Two investigators 
conducted the interviews using a purpose-
designed guide (see Supplementary File 1),  
which was informed by expert opinion 
and empirical research in the fields of 
asthma and health economics. Broadly, 
interviews canvassed patients’ and carers’ 
understanding, choices and use of asthma 
medicines; factors affecting their decision 
to take or give their children preventer 
medicines; and potential acceptability of 
differential co-payment arrangements for 
different preventer medicines.
Recruitment
Participants were recruited through the 
contact list of a consumer organisation 
(Asthma Foundation NSW, now Asthma 
Australia) and through a practice-based 
research network in a less privileged area 
of the Sydney metropolitan region. This 
ensured sampling of participants in a range of 
socioeconomic areas. Recruitment continued 
until data saturation was reached. 
Data collection and analysis
Interviews were digitally recorded and 
transcribed verbatim using TapeACall Pro. 
Interviewees were assigned pseudonyms 
for reporting purposes. A code framework 
was developed and agreed by two authors 
(SD, HR). Due to the exploratory nature of 
the topic, a descriptive qualitative design, 
combining empirical and grounded 
theory approaches was used for analysis. 
Emergent themes and divergent views were 
identified and discussed, and differences 
between patients and carers, and across 
socioeconomic categories, were explored. 
Transcripts were revisited frequently during 
analysis to confirm the validity of themes. 
Ethics
Ethics approval was granted by the University 
of New South Wales Human Research 
Advisory Panel (#HREAP-2014-7-34). All 
participants provided informed consent. 
Results
Twenty-four adults with asthma and 20 carers 
for a child with asthma were interviewed 
(one adult was also interviewed as a carer 
so total participants n=43). Males (n=13) 
comprised 54% of the adult interviewees. 
Participants came from major cities (n=33, 
77%), inner regional (n= 8, 19 %), and outer 
regional areas (n=2, 0.5%).16 Just over one-
quarter of participants were concession 
card holders. One-third of participants were 
recruited from Asthma NSW (14/43), with the 
remainder sourced via medical practices in 
South Western Sydney. Further demographic 
information is available in Table 1.
Participants’ experiences of asthma 
and medicine use
The interviews elicited information about 
participants’ overall experience of having 
asthma, or being a carer for a child with 
Box 1: Australian Pharmaceutical Benefits Scheme 
[PBS]
The Pharmaceutical Benefits Scheme is an Australian 
Government scheme that subsidises medicine costs for all 
Australians. A patient co-payment is usually required, paid 
to the pharmacist at the time of dispensing. Currently (from 
1 January 2019) the maximum patient contribution per 
prescription dispensed is $40.30 for general beneficiaries, or 
$6.50 for concession cardholders. The government pays the 
remaining cost. 
The PBS Safety Net reduces the cost of prescription medicines 
for individuals and families who reach the threshold of 
$1,550.70 per year (general), or $390.00 (concession). 
The safety net patient contribution is then $6.50 (general 
beneficiaries) or free (concession cardholders) for the 
remainder of the calendar year. 
Table 1: Participant characteristics.
Adults with asthma 
n=24
Carers of children with asthma 
n=20 
(21 children aged 3-17)
Gender Female: 11 (46%)
Male: 13 (54%)
Interviewee 
     Female: 20 (100%)
Children:
     Male: 13 (62%)
     Female: 8 (38%)
Index of Relative Socio-economic Advantage 
and Disadvantage (IRSAD)a
Quintile 1b: 10 (42%)
Quintile 2: 3 (13%)
Quintile 3: 4 (17%)
Quintile 4: 2 (8%)
Quintile 5: 4 (16%)
unknown: 1 ( 4%)
Quintile 1: 7 (35%)
Quintile 2: 6 (30%)
Quintile 3: 2 (10%) 
Quintile 4: 0 (0%)  
Quintile 5: 5 (25%)
Concession card holderc 8 (33%) 4 (20%)
Current asthma preventer used None: 7 (29%)
ICS alone: 2 (8%)
ICS/ LABA: 15 (63%)
LTRA: 0 (0%)
None: 3 (14%)
ICS alone: 12  (60%)
ICS/ LABA: 3 ( 14%)
LTRA: 8 (40%)
Notes:
ICS: inhaled corticosteroid; ICS/LABA: inhaled corticosteroid/long-acting beta2-agonist; LTRA: leukotriene receptor antagonist
a: The Index of Relative Socio-economic Advantage and Disadvantage (IRSAD) summarises information about economic and social conditions of people and 
households within an area identified by postcode of residence; where ‘1’ is the most disadvantaged and ‘10’ is the most advantaged. 
b: Pairs of deciles have been combined into quintiles for ease of reading. For example, Quintile 1 refers to Deciles 1 and 2.
c: Healthcare cards are specific government-issued cards entitling the holder to various health benefits or concessions (e.g. supply of pharmaceuticals free of 
charge or at reduced rates). These include treatment entitlement card from the Department of Veterans’ Affairs; Health Care Card (including for low income 
earners and foster carers); Pensioner Concession Card and Commonwealth Seniors Health Card.
d: Asthma preventer medicines are intended for regular maintenance use, to reduce symptoms and risk of exacerbations. Adults and children could have been 
on more than one preventer medicine, so totals may add up to more than 100% 
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asthma, and their use and understanding 
of asthma medicines. Co-morbidities such 
as allergic rhinitis and allergies contributed 
to participants’ overall asthma experience. 
Participants spoke about the effect of asthma 
on their quality of life, usually in negative 
terms, affecting every facet of daily life to 
varying degrees. However, most perceived 
their asthma as “OK” provided they were 
taking their medicines as prescribed. The 
majority of participants revealed that they 
attended their doctor only if they were 
symptomatic and not for regular asthma 
review. By contrast a handful of carers were 
more proactive, with their child’s health 
being the priority and not something to be 
compromised. 
Knowledge of different classes of asthma 
medicine varied widely, from rudimentary 
knowledge to being able to name preventers 
that other people may be using. Of those 
using a combination ICS/LABA (63% adults, 
14% children), few seemed to know that this 
contained a preventer and a bronchodilator. 
Information seeking and confidence in 
discussions with healthcare providers 
(HCPs) appeared to differ depending on 
the recruitment source, with participants 
recruited via the consumer organisation 
exhibiting higher levels of engagement. 
Themes around asthma preventer 
medicines
Three major themes were explored (see  
Table 2):
•	 Influences on decisions about preventer 
choice
•	 Barriers and enablers to preventer 
adherence
•	 Perceptions around cost of medicine.
Influences on decisions about 
preventer choice
Participants’ comments shed substantial 
light on their experience of conversations 
with HCPs about medicine choice and their 
comfort with initiating such discussions. 
Some participants were comfortable with 
discussing preventer rationale or choice 
with HCPs, but described it as having their 
questions answered rather than in-depth 
shared decision making. In fact, both adults 
and carers placed the responsibility for 
medicine changes firmly with the doctor, 
citing reasons such as lacking the requisite 
expertise and, frequently, that this was not 
their role as a patient or carer:
Well, it’s not like I went in there and said to 
him, “I’ve decided my son needs a preventer.” 
… It’s just not what I do as a parent, a parent 
of a patient. That’s not my job, it’s the doctor’s 
job, you know (Yolande, carer-IRSAD 3)
When probed about factors that would affect 
decision making about preventer choice, if 
this were offered, treatment effectiveness 
was the key factor for most participants. 
This was particularly evident for carers, who 
additionally wanted their child to have as 
normal a life as possible. 
So long as it works. That’s all that matters 
(Miriam, carer-IRSAD2)
Participants’ decision making was also 
influenced by recommendations from family 
and friends, often related to the availability of 
new medicines: 
My nephew has asthma like my son, and if he’s 
having better results on a different medicine 
and my sister discussed that with me ... then 
I would ask, or recommend something with 
my GP. (Mai, carer-IRSAD2)
Barriers and enablers to preventer 
adherence
Barriers
Participants reported more barriers than 
enablers. Barriers included participant 
behaviours, medicine-related factors such as 
side effects and cost, and characteristics of 
healthcare professionals. 
Participants’ responses revealed a number 
of behaviours such as skipping doses or 
delaying refills, associated with intentional 
and unintentional lack of adherence. 
Intentional non-adherence factors included 
concerns about the need for regular medicine 
use per se and the perceived stigma of 
using asthma medicines in front of others. 
Non-intentional factors included forgetting 
and out-of-pocket medicine costs. Some 
participants reported not being able to judge 
if the preventer was actually working and 
therefore whether it was required:
Then you stop taking it for a few days and then 
when it [asthma] comes back up and then, 
you know, you realise you need it. So  … you 
know, you don’t think it’s that important and 
when it’s important you take it, that sort of 
mentality … (Eduardo-IRSAD-8)
Some behaviours related specifically to 
children, such as their ability to co-operate 
and use devices correctly. Having a chronic 
disease was noted by one carer as adding 
an extra layer of responsibility onto children. 
Several carers expressed a dislike of giving 
any medicine to their child and some actively 
searched for alternative therapies to avoid 
medicine use:
We went to a Naturopath, recommended 
by someone whose daughter was cured of 
asthma, and I used to go monthly (Shivon-
IRSAD3)
The barrier most often cited by participants 
related to perceived side effects of asthma 
medicines, particularly corticosteroids. 
For some adults weight gain from oral 
corticosteroids was the major concern. 
Instead, for carers, possible effects of ICS on 
growth of children were paramount. Whilst 
some carers saw corticosteroids as a last 
resort, other had weighed up the risks and 
benefits and decided to give the preventer to 
their child:
The only side effect I am aware of is the, the 
fact that it’s got steroids and they, you know, 
can cause growth [sic] or that sort of thing. 
But the amount of steroids in it, from what I’ve 
learnt, is very minor. So no, the side effects are 
not a factor for us giving him the preventer. 
(Amanda, carer-IRSAD2)
Carers were also aware from media activity 
of a link between LTRAs and mental health 
issues, including suicidal thoughts, and were 
concerned about the lack of long-term safety 
data: 
I would be concerned about the safety and 
side effects as well, because … more than 
anything else … one of the Doctors at the 
beginning wasn’t keen on [LTRA], because it 
was a newer drug and there wasn’t enough 
historical data to look at it. I mean, we still 
went ahead with it, but actually it was a valid 
point (Donna, carer-IRSAD4)
Characteristics of HCPs, including behaviours 
and accessibility, represented another barrier. 
Table 2: Themes and subthemes.
Influences on decisions about preventer choice
Perceived responsibility for medicine changes
Perceived effectiveness of prescribed asthma medicines
Influences of family and friends
Barriers and enablers to preventer adherence 
Characteristics of medicine e.g. side effects; perceived lack 
of effect; cost
Participant behaviours
Characteristics of healthcare professionals + communication 
skills 
Perceptions around cost of medicines
Primacy of health
Patients’ innate characteristics and current circumstances
Societal affordability/ government responsibility
Cost of not taking medicines
Prompted perceptions around cheaper preventers
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Some participants perceived HCPs as poor 
communicators – not “hearing” the patient, or 
adequately educating them:
I was angry at the professionals that hadn’t 
given me the time, that hadn’t properly 
explained things to me … I have found the 
whole process tremendously trial and error, 
and very frustrating. (Jenny, carer-IRSAD5)
Practical issues such as the need (and cost) 
to visit a doctor to obtain scripts, and the 
availability of medicines and accessories in 
pharmacies were perceived to be a problem 
especially in rural areas:
Some chemists … keep in stock for you, and 
it’s usually not the local chemist, it’s usually 
one that you’ve got to travel a good half hour 
away to. (Tina, carer-IRSAD4)
Enablers
Enablers of good adherence mentioned by 
participants included strategies such as a 
sense of accountability to their HCP, visual 
cues to remember to take medicine, and 
development of good habits, which assisted 
them or their child in self-monitoring their 
asthma status and control:
[On a chart, we] have a little picture of [his 
medicine] there, see that that’s part of his 
tasks to do. And you know, that’s all built 
into a bit of rewards … I think that’s really 
important, that people think about the 
strategies as well, to sort of reinforce that good 
health habit. (Tina, carer-IRSAD4)
Support from HCPs was helpful to carers 
especially around time of diagnosis, as they 
provided information and reduced stress:
The asthma Nurse … when Angelina was first 
diagnosed, this lady came to our place to talk 
to us about asthma … and I felt very grateful 
to have been able to talk to someone about 
that, because it’s a very stressful time …  it is to 
do mostly with the time and the quality of the 
information. (Donna, carer-IRSAD4)
Factors related to inhaler devices such as the 
presence of a dose counter were reported 
by both carers and adults with asthma as 
assisting with preventer use:
It was good to see that the [ICS/LABA] actually 
had a counter on it, whereas your [ICS alone] 
didn’t; that was something useful. The other 
thing, we’ve actually bought [name] too, to 
help administer is one of those little aids, to 
help with his hand, so it’s easier to push it 
down (Tina, carer-IRSAD4)
Finally, some participants’ interview responses 
revealed the importance of preventers in 
maintaining their independence and ability 
to participate in social and physical activities:
Well it just allows me to do things. It means 
I’m not reliant on a medical system to, you 
know, bring me back to life. I can just get on 
with things, doing what I need to do. Before 
preventers and relievers, people would have 
been just sitting on the sidelines, just on the 
sidelines of life. We don’t have to anymore. 
(Robert-IRSAD1)
Perceptions around cost of medicines 
Participants spontaneously mentioned cost 
issues as a barrier to preventer use during 
the interviews, however, it was not a focus 
for most participants. Most participants 
prioritised health over medicine cost; with the 
primacy of health came a resignation to the 
need for medicine and a willingness to pay. 
Moreover, several carers expressed that they 
would go without if it meant getting their 
child the treatment that he/she needed: 
Look love, I’d find a way. I’d find a way. You’ve 
got to breathe, you know? (Connor-IRSAD5)
First is our son’s health. So I would pay, you 
know, all my wage into keeping my son 
healthy (Miriam, carer-IRSAD2)
The main medicines that were perceived to 
be expensive were LTRA tablets (for adults at 
the time (prior to the availability of generic 
substitutes), around $70 for a month’s supply), 
and ICS/ LABA inhalers, by comparison with 
reliever inhalers. For some participants, cost 
contributed to intentional non-adherence 
and worse asthma control:
I’m a bit slack ‘cause the [ICS/LABA]’s pretty 
expensive and if I, if I sort of can’t afford it, I’ll 
go without it for a couple of months and … I 
notice it really, really badly (Anthony, IRSAD 
not known)
I have quite a long list of medications, 
actually, so yeah it does [impact on what I 
take], definitely. Sometimes I don’t take my 
arthritis medicine, you know? Sometimes I 
can’t afford all the scripts so I have to weigh 
up which scripts I need most at the time 
(Megan, IRSAD2).
Several participants reported being unaware 
of medicine costs until actual purchase, as 
costs were only raised by the pharmacist:
They never tell you at the [consultation], “Oh, 
this is going to cost you so much … until you 
go to your pharmacist  … they tell you the cost 
(Mai, carer-IRSAD2)
Several participants who were eligible 
for reduced (concessional) co-payments 
expressed that medicine costs could still be 
a struggle, and they may need to go without 
medicine, lower their dose or frequency of 
use temporarily, or make a sacrifice in some 
other area. Others, noting that they had lower 
out-of-pocket costs for medicines, reported 
feeling lucky and likely to be non-adherent 
otherwise:
I’m entitled to a health care card. Before then, 
that was where it had come down to with the 
[ICS/ LABA], with me going, “Okay, can I afford 
it this week?” … you wouldn’t take it for a 
week, because you’re looking at how many 
puffs are left on it (Melinda-IRSAD1)
The affordability of asthma medicines at a 
societal level was also a concern for many 
participants, with the government seen to 
have an important role. Several participants 
expressed that patients cannot help suffering 
from diseases such as asthma and shouldn’t 
have their treatment compromised because 
of cost:
I think it’s absolutely reasonable and the right 
thing to do, that chronic illnesses, things that 
nobody did anything wrong to get them, they 
should be able to access affordable medicines. 
(Yvonne, carer-IRSAD2)
Importantly, the cost of not taking medicines 
was raised by several participants, noting 
both direct costs (relating to the person’s 
health) and indirect costs (such as lost wages 
and decreased workforce productivity) were 
associated with omitting asthma medicines: 
You don’t want to put your child into hospital 
because you wanted to save a buck, you 
know? (Merryl, carer-IRSAD3)
The cost if I don’t take it is higher, because 
when you take time off work, that costs you 
money, or costs me money… because if you’re 
always sick and stuff like that and can’t catch 
up with your work … (Hasham-IRSAD1)
Finally, some participants mentioned that 
costs may be influenced by pharmaceutical 
manufacturers:
I  think I ’m naturally suspicious of 
pharmaceutical companies, and so I 
would think, “Well, what’s the deal for this 
pharmaceutical company, and what’s the 
deal for the government here with this one?” 
(Jenny, carer-IRSAD5)
At the end of the interview, participants’ 
understanding of patient co-payments was 
explored and they were also presented with 
hypothetical scenarios concerning availability 
of cheaper or free preventers. The concept 
that what was paid to the pharmacist was a 
co-payment to government for part of the 
cost of the medicine was poorly understood 
overall. Several participants confused 
these payments with Medicare payments 
to healthcare professionals. The need for 
more education regarding co-payments 
Davis et al. Article
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was expressed by a couple of participants, 
suggesting that this concept is not explained 
routinely to patients:
Well we’ve never really been told what the 
gap is … how much does it really cost for 
that medicine, and how much are we being 
charged? (Mai, carer-IRSAD2)
When asked whether lower co-payments 
for asthma medicines would affect their 
purchasing behaviours, participants’ 
responses varied depending on the priority 
they ascribed to their health, the importance 
they placed on preventer use and whether 
they had a healthcare card. Several 
participants noted that circumstances might 
change in this regard:
Yes, definitely ‘cause I am … we’re a one-
income family. If we didn’t have a healthcare 
card, we would really find it quite hard, 
especially one of these preventers, when I 
found out the full cost was $70 without a 
$6.10, you know, healthcare card. (Michaela, 
adult and carer-IRSAD2)
Concerning the hypothetical scenario of a 
lower patient co-payment for only some 
medicines (ICS-alone), several participants 
saw this as inequitable, particularly if the 
treatment needs of individual patients would 
not be taken into account; they felt that 
extensive justification would be needed. 
Moreover, the notion of free preventers was 
generally viewed with scepticism:
But you know, like anything for free, you often 
get a bit suspicious as to what’s the catch: Is it 
faulty? Is it going to work? What’s the story? 
(Tracey, carer-IRSAD4)
Discussion
The findings of this qualitative study of 
adults with asthma, and carers of children 
with asthma, provide important insights 
into the quality use of asthma preventer 
medicines in Australia and the role of cost 
in patient decision making. Notably, there 
were multifactorial influences on participants’ 
decisions about preventer choice, including 
perceived effectiveness of prescribed asthma 
medicines, and ease of communication 
with HCPs. However, participants’ responses 
regarding perceived responsibility for 
medicine changes showed they had little 
actual experience of shared decision-making. 
Participants revealed a number of barriers 
and enablers to preventer adherence, 
once a medicine had been dispensed, and 
they provided useful feedback regarding 
asthma medicine costs, as well as the likely 
effect on their purchasing behaviours with 
hypothetical changes to prescription co-
payments.
Factors influencing decisions about 
preventer choice
This study showed that effectiveness of 
preventer medicines, in promoting good 
asthma control, was the stated priority for 
participants. Maintenance of health was 
prioritised above cost by most participants, 
particularly carers. 
The concept of shared decision making 
around responsibility for medicine decisions 
did not resonate with many participants in 
this study. Shared decision making, which 
warrants that HCP and patient share relevant 
information, express treatment preferences, 
deliberate the options, and agree on the 
treatment to implement,17-19 is known 
to improve adherence and outcomes.17 
However, although some participants 
reported discussing treatment options with 
their doctor, most did not regard themselves 
as primary decision makers about preventer 
use. These findings mirror UK research in 230 
adults with asthma, where most perceived 
that their role was passive or semi-passive 
in respect of treatment decisions.20 In a 
qualitative study of Australian GPs’ views on 
the influence of cost on prescribing of asthma 
preventer medicines, GPs reported that 
they did not initiate discussions of cost with 
patients, and they did not mention a role for 
the patient in making the decision, other than 
one GP noting that “some patients expressed 
difficulty affording medicines, not just for 
asthma”.15
Concerning barriers and enablers to 
preventer adherence 
Most participants agreed that preventers 
were indeed important in maintaining 
good asthma control and quality of life. 
Despite this, they revealed that in practice 
they may be poorly-adherent, with cited 
barriers representing both intentional and 
unintentional behaviours. 
The types of barriers reported in the 
current study are in line with those cited in 
Australian and international asthma research, 
including (lack of) perceived necessity of 
medicines, ease of use, and concerns about 
and experience of medication side effects.10 
The balance between necessity vs. concerns 
is well acknowledged in the literature; 
patients are more likely to take a treatment 
if “convinced that it is necessary to maintain 
or improve our health now and in the future, 
have few concerns about negative effects, 
and can overcome the practical difficulties 
in following the regimen (e.g. forgetting, 
difficulties using the administration device, 
and affording co-payments).”21
In our study participants mentioned 
behaviours such as reducing their prescribed 
dose, or going without for a couple of 
months; they did not necessarily perceive 
this as stopping their medicine, but rather 
titrating depending on cost. This behaviour 
is similar to that cited in a literature review 
of patients at risk for cost-related medicine 
non-adherence where participants delayed 
or failed to fill prescriptions, cut dosages and 
reduced the frequency of administration.22 
Some of our participants, when faced with 
cost pressures, prioritised which medicine(s) 
to reduce based on their perceived 
importance to their health. 
Characteristics of GPs, including their 
ability to communicate, were of concern 
to participants in this study. Lack of shared 
decision making appeared to have been 
exacerbated in many cases by perceived 
inadequacies in HCP communication. The 
need for more education and adequate 
consultation time was also identified, but it 
may be difficult for HCPs to incorporate self-
management topics during consultations.23 
By contrast, several participants indicated 
their willingness to use preventers due to 
their implicit trust in their HCP’s knowledge 
and the ongoing respectful relationship 
with them. Opportunities for collaboration 
are enhanced when patients perceive 
relationships as trusting, empathic and 
positive, fostering a sense of being respected 
and cared for by healthcare professionals.24
Concerning perceptions around cost 
of medicines
There was heterogeneity between 
participants in this study regarding the 
impact of medicine cost. For a few, medicine 
affordability critically affected their quality 
of life; however most stated that they would 
prioritise health above medicine cost. While 
this may reflect social desirability bias, it is in 
line with results of a UK qualitative study that 
concluded that “the impact of prescription 
charges on asthma patients is uneven and 
unpredictable”.12 Participants in the current 
study also noted that financial circumstances 
are fluid, not fixed, and may change at any 
time.
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Further regarding medicine costs, responses 
in this study suggest that, although 
medicine costs are factored into patients’ 
decision making, doctors do not routinely 
discuss these costs and a pharmacist is 
more likely to give this information to the 
patient at the point of purchase. Our results 
support previous research suggesting that 
doctors are not knowledgeable about the 
cost of medicines to patients and do not 
discuss costs when prescribing.15,25 This is 
unfortunate, as prescribers might otherwise 
“be able to reduce the impact of cost by, for 
example, prescribing generic or lower cost 
medicines when appropriate”.26 
Understanding of co-payments
Overall, participants in this study had a very 
limited understanding of the concept of 
co-payments and it was therefore difficult 
to draw conclusions regarding the success 
of possible government changes to co-
payments for asthma preventer medicines, 
including ICS-alone. Other authors have 
argued that for incentive-based formularies 
(tiered co-payments) to operate as intended, 
consumers must be aware of cost-sharing 
information about prescription drugs and 
communicate their preferences.27
Proposed solutions
Our results suggest that to address preventer 
adherence issues, including cost, support 
is required for both HCPs and patients. 
Regarding HCPs, who have been identified 
in previous research as lacking information 
about medicine costs,15,28 prescribing 
decision support should include real-time 
data on the relative costs of therapeutically 
equivalent medicines.26,28 For asthma 
preventers, with multiple doses and devices 
available, these costs are not necessarily easy 
to calculate.14,26 Armed with this information, 
GPs would be in a position when considering 
asthma treatment choices to “empathically 
explore with the patient whether cost-related 
non-adherence is an issue”.15 
Patient-centred communication strategies 
are crucial in facilitating participation 
of patients.11,20 Providing HCPs with 
communication training, for example in non-
confrontational motivational interviewing 
techniques, can lead to improved patient 
health behaviours and medicine adherence.29 
Pharmacists also have an important 
communication role in promoting 
adherence, both in medicine counselling, 
and in suggesting lower-cost brands where 
possible.27 Both pharmacists and GPs should 
be aware of the option of lower out-of-pocket 
costs with guideline-recommended ICS-alone 
treatment.15,26
As free medicine and other financial 
incentives were met with scepticism by 
participants in our study, we believe that 
measures such as lower patient co-payments 
for ICS-alone would need to be accompanied 
by substantial education for patients and 
GPs about the relative efficacy of treatment 
options as well as the rationale behind co-
payments in general. 
Study limitations and strengths
Strengths of this study include the insights 
provided on how patients and carers make 
decisions around asthma preventer choices, 
with participants sampled from a broad range 
of socioeconomic backgrounds. It is the first 
study to canvass patients’ views on how 
different hypothetical funding models for 
preventer medicines might affect them.
Regarding limitations, the study was 
conducted in one geographical area 
(NSW) and we were not able to recruit any 
male carers for interview, which may limit 
generalisability. Due to heterogeneity among 
participants regarding the importance of 
medicine cost, it was not possible to draw 
any firm conclusions about the effects of 
relative advantage or disadvantage on the 
perceptions of participants regarding costs. 
No objective measures of patient behaviour 
were available and participant responses 
about priorities, as in any qualitative research, 
could have been subject to social desirability 
bias.30
Practice implications
•	 Asthma patients and carers of children 
with asthma could benefit from education 
regarding shared decision-making, to 
empower them in their dealings with HCPs 
and choices of medicine.
•	 HCPs, including GPs, need to be aware of 
the medicine choices that are available and 
actively encourage patient engagement. 
•	 This study confirmed the important effect 
of cost in adherence for many patients. 
General practitioners need to encourage 
empathic discussion about barriers and 
enablers.
•	 At a policy level, both HCPs and patients 
need to be provided with information 
about the relative costs of asthma 
medicines and the role of co-payments. 
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